Oral Minoxidil in Androgenetic Alopecia: How It Works, Efficacy, and Safety

Within the medical management of hair loss, oral minoxidil has established itself as one of the most effective and convenient tools for treating androgenetic alopecia in both men and women.

Although traditionally used as a topical lotion, its administration in low-dose tablets has significantly improved treatment adherence and clinical hair response in consultation.

Table of Contents

1. What is androgenetic alopecia and why does hair miniaturize?
2. From topical use to tablets: how does oral minoxidil work?
3. Usual doses and advantages of the oral route
4. The role of combined treatment with antiandrogens
5. Oral minoxidil before and after a hair transplant
6. The shedding effect and what happens if you stop taking it
7. Safety, regulation, and potential side effects
8. Frequently asked questions
9. References

1. What is androgenetic alopecia and why does hair miniaturize?

Androgenetic alopecia is the most common cause of hair loss in both men and women. It does not appear suddenly, but rather progresses gradually as genetically predisposed hair follicles respond to the action of dihydrotestosterone (DHT), becoming progressively smaller.

This phenomenon is known as follicular miniaturization: the hair loses caliber and density, and its growth phase is shortened. In our clinics in Madrid and Mexico City, we see patients every day who consider low-density areas to be completely lost when, in reality, miniaturized hair is still present and can be recovered with the appropriate pharmacological treatment.

2. From topical use to tablets: how does oral minoxidil work?

Minoxidil is a medication with a long track record. It was first used in the 1980s to treat high blood pressure (in doses of 10 to 40 mg daily) due to its arteriolar vasodilator effect. In those patients, a striking side effect was observed: hair thickening and the stimulation of hair growth (hypertrichosis).

At the capillary level, minoxidil acts directly on the hair follicle through several mechanisms:

• Improves vascularization: as a vasodilator, it optimizes blood flow and nutrient delivery to the follicle.
• Modulates the hair cycle: it prolongs the growth phase (anagen) and shortens the resting or shedding phase (telogen).
• Thickens the hair shaft: it increases follicle size and reverses miniaturization, improving the caliber of existing hair.
• Biochemical stimulation: it increases prostaglandin production and is linked to the activation of the Wnt/β-catenin pathway, which is involved in follicular cycle regeneration.

3. Usual doses and advantages of the oral route

Although initially marketed as a lotion, the transition to tablet form (often through personalized compounding after a prior blood test) has brought a major clinical advantage. Because it is absorbed systemically, it ensures maximum efficacy and avoids the cosmetic inconveniences of topical solutions (greasy hair, itching, flaking, or scalp irritation).

In trichology, it is always used in low doses (low-dose oral minoxidil), far below those once used for blood pressure:

• In women: usually between 0.25 mg and 1 mg per day.
• In men: around 2.5 mg to 5 mg per day.

It is recommended to take it preferably at night and to strictly follow the schedule prescribed by the medical specialist. Exceeding the dose will not increase hair growth or make it work faster, but it can increase side effects.

4. The role of combined treatment with antiandrogens

In clinical practice, the most effective approach to androgenetic alopecia is usually combined pharmacological treatment.

While antiandrogen medications such as Finasteride or Dutasteride target the hormonal cause by blocking the 5-alpha reductase enzyme to halt the progression of hair loss, Minoxidil acts as a potent follicular stimulator that thickens and improves hair quality. Both mechanisms complement each other to stabilize hair loss and restore density.

5. Oral minoxidil before and after a hair transplant

Oral medication and hair transplantation are part of the same therapeutic approach. Prescribing oral minoxidil (alongside hormonal stabilizers depending on each case) before and after a hair transplant helps to:

• Strengthen the donor and recipient areas prior to surgery, even reducing the number of follicular units needed by recovering miniaturized hair.
• Increase graft survival rates and prepare the follicle for surgical stress.
• Protect native hair to prevent alopecia from progressing and compromising the long-term aesthetic result of the transplant.

6. The shedding effect and what happens if you stop taking it

There are two key aspects every patient should know when starting treatment with minoxidil:

The initial shedding effect

During the first 3 to 4 months of treatment, it is normal to experience a temporary increase in hair loss. This process, known as the shedding effect, occurs because follicles in the telogen (resting) phase are shed to make way for a new growth cycle in the anagen phase with stronger hair. It is a sign that the medication is working and does not lead to a noticeable loss of hair density.

Consequences of stopping the treatment

Minoxidil does not permanently cure androgenetic alopecia; its effectiveness relies on consistency. Stopping Minoxidil for more than two months will cause the thickened follicles to progressively lose their gained caliber and return to the diameter they had before starting treatment. There is no scientifically proven “rebound effect” that leaves the patient worse off than at the beginning, but rather a gradual return to the baseline state.

7. Safety, regulation, and potential side effects

Regarding regulation by agencies such as the FDA and the EMA, oral minoxidil for androgenetic alopecia is prescribed off-label, a standard medical practice when backed by robust scientific evidence and extensive clinical experience.

At low doses, it is well tolerated by most patients, although it requires a prior medical evaluation (especially if taking blood pressure medication, if there is a history of cardiac, renal, or hepatic conditions, or during pregnancy or breastfeeding). The most common side effects can usually be managed by adjusting the dose and include:

• Hypertrichosis: increased growth of facial or body hair.
• Mild headache: may occur during the first 4 or 5 days of treatment and subsides on its own.
• Fluid retention or mild swelling in the ankles, hands, or face.
• Palpitations, dizziness, or changes in blood pressure.

8. FREQUENTLY ASKED QUESTIONS

Who should prescribe oral minoxidil?

Minoxidil must be prescribed by a physician specializing in trichology, such as Dr. Espinosa Custodio. Following a diagnostic consultation and a blood test to check specific parameters, the doctor will prescribe the personalized dose best suited to your case.

How long does it take to see results from oral minoxidil?

After passing the initial shedding phase (between the first and third or fourth month), hair loss stabilization and hair thickening begin to become visible from 4 to 6 months onwards, reaching peak results around one year of consistent use.

Can oral medication be replaced by mesotherapy or PRP?

Currently, not completely. Treatments such as hair mesotherapy or PRP are very useful as supportive therapies within a comprehensive approach to androgenetic alopecia, but they do not replace the systemic effect or adherence offered by oral medication.

Dr. Espinosa Custodio practices at the Instituto Médico del Prado, his hair clinic in Madrid or in Mexico City. If you wish to book an appointment, you can contact us by phone at +34 912 468 664, on WhatsApp at +34 627 396 322, or through the contact page on our website. If you are contacting us from Mexico, our phone number is +52 55 4590 9909.

9. References

• Gupta AK, Talukder M. Efficacy and safety of low-dose oral minoxidil for androgenetic alopecia: a systematic review. Journal of the American Academy of Dermatology. 2021;84(3):737–746.
• Rossi A, Cantisani C, Melis L, et al. Minoxidil use in dermatology, side effects and recent patents. Recent Patents on Inflammation & Allergy Drug Discovery. 2012;6(2):130–136.
• Ramos PM, Sinclair RD. Management of androgenetic alopecia: a review. Dermatologic Clinics. 2015;33(1):1–12.